Fast Five Quiz: Refractory Myasthenia Gravis

Raghav Govindarajan, MD


October 13, 2021

One of the primary goals of developing therapy options for patients with MG is targeting the distinct phenotypes of the disease. For the patient population with refractory MG, three emerging monoclonal antibody–based therapies include rituximab, eculizumab, and belimumab.

Rituximab appears to work more effectively in patients with anti–MuSK-positive MG than in patients with anti–AChR-positive disease. Eculizumab, on the other hand, specifically targets complement activation involved in anti–AChR-positive MG and therefore has the most potential for efficacy in this patient subpopulation. To date, results from a randomized trial evaluating the efficacy of belimumab for patients with anti–MuSK-positive MG and anti–AChR-positive MG did not show statistically significantly different results in the treatment arm.

Learn more about medication use in patients with MG.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.